Amyloid Plaque Reduction as a Surrogate Marker of Efficacy: Assessment of Amyloid PET and Change in CDR‐SB Utilizing Semi‐Mechanistic Model

Brian A Willis, Pratik Bhagunde, Robert Bell, Natasha Penner, Arnaud Charil, Michael C Irizarry, Steven Hersch, Larisa Reyderman · 2025

Read Amyloid Plaque Reduction as a Surrogate Marker of Efficacy: Assessment of Amyloid PET and Change in CDR‐SB Utilizing Semi‐Mechanistic Model by Brian A Willis, Pratik Bhagunde, Robert Bell, Natasha Penner, Arnaud Charil, Michael C Irizarry, Steven Hersch, Larisa Reyderman (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11712377.txt.

Description

Brian Willis and co-authors model amyloid plaque loss as a stand-in for drug benefit in Alzheimer disease in this 2025 paper. Lecanemab is an antibody that binds amyloid protofibrils and clears plaques. Brain scans can track that clearing, but whether scan change predicts slower decline needed a test.

The team pooled data from two lecanemab trials, one phase two and one phase three. A semi-mechanistic model linked amyloid PET change to change on a dementia rating scale. Placebo data set the natural pace of decline in the model. Treated data then showed how plaque loss bends that pace. Simulations projected treatment effects over four years of use.

Catalog record

CREATORBrian A Willis, Pratik Bhagunde, Robert Bell, Natasha Penner, Arnaud Charil, Michael C Irizarry, Steven Hersch, Larisa Reyderman
YEAR2025
COLLECTIONPAPERS
FORMATTXT
FILE SIZE3 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC11712377

Browse the full library · About the Tower of Babel